CN1471517A - Cxazolyl-芳基丙酸衍生物及其作为过氧化物酶体增殖物活化受体激动剂的用途 - Google Patents
Cxazolyl-芳基丙酸衍生物及其作为过氧化物酶体增殖物活化受体激动剂的用途 Download PDFInfo
- Publication number
- CN1471517A CN1471517A CNA018177387A CN01817738A CN1471517A CN 1471517 A CN1471517 A CN 1471517A CN A018177387 A CNA018177387 A CN A018177387A CN 01817738 A CN01817738 A CN 01817738A CN 1471517 A CN1471517 A CN 1471517A
- Authority
- CN
- China
- Prior art keywords
- methyl
- compound
- phenyl
- propionic acid
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22723400P | 2000-08-23 | 2000-08-23 | |
| US60/227,234 | 2000-08-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1471517A true CN1471517A (zh) | 2004-01-28 |
Family
ID=22852309
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA018177387A Pending CN1471517A (zh) | 2000-08-23 | 2001-08-23 | Cxazolyl-芳基丙酸衍生物及其作为过氧化物酶体增殖物活化受体激动剂的用途 |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US6930120B2 (https=) |
| EP (1) | EP1313716B1 (https=) |
| JP (1) | JP2004506721A (https=) |
| KR (1) | KR20030027054A (https=) |
| CN (1) | CN1471517A (https=) |
| AT (1) | ATE361283T1 (https=) |
| AU (1) | AU2001284659A1 (https=) |
| BR (1) | BR0113409A (https=) |
| CA (1) | CA2418104A1 (https=) |
| CY (1) | CY1107679T1 (https=) |
| CZ (1) | CZ2003482A3 (https=) |
| DE (1) | DE60128239T2 (https=) |
| DK (1) | DK1313716T3 (https=) |
| EA (1) | EA200300286A1 (https=) |
| EC (1) | ECSP034504A (https=) |
| ES (1) | ES2286137T3 (https=) |
| HU (1) | HUP0300857A3 (https=) |
| IL (1) | IL154110A0 (https=) |
| MX (1) | MXPA03001558A (https=) |
| NO (1) | NO20030729L (https=) |
| NZ (1) | NZ523804A (https=) |
| PL (1) | PL360744A1 (https=) |
| PT (1) | PT1313716E (https=) |
| SK (1) | SK1872003A3 (https=) |
| WO (1) | WO2002016331A1 (https=) |
| ZA (1) | ZA200300570B (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004509084A (ja) * | 2000-08-23 | 2004-03-25 | イーライ・リリー・アンド・カンパニー | オキサゾリル−アリールオキシ酢酸誘導体およびそのｐｐａｒアゴニストとしての使用 |
| AU2001284660A1 (en) | 2000-08-23 | 2002-03-04 | Eli Lilly And Company | Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists |
| DE60211891T2 (de) * | 2001-05-15 | 2007-05-24 | F. Hoffmann-La Roche Ag | Carbonsäure-substituierte oxazol-derivate zur verwendung als ppar-alpha und -gamma aktivatoren zur behandlung von diabetes |
| KR100459917B1 (ko) * | 2001-12-14 | 2004-12-03 | (주)바이오뉴트리젠 | 페놀릭산 유도체 및 이를 포함하는 혈중 지질 농도 관련질환의 예방 및 치료용 조성물 |
| US6867224B2 (en) | 2002-03-07 | 2005-03-15 | Warner-Lambert Company | Compounds that modulate PPAR activity and methods of preparation |
| US6833380B2 (en) | 2002-03-07 | 2004-12-21 | Warner-Lambert Company, Llc | Compounds that modulate PPAR activity and methods of preparation |
| BR0312452A (pt) | 2002-07-03 | 2005-04-19 | Hoffmann La Roche | Composto; processo para a preparação de um composto; composição farmacêutica; uso de um composto; e método para o tratamento e/ou profilaxia de doenças que são moduladas por agonistas de ppar(alfa) e/ou ppar(gama) |
| KR100736955B1 (ko) * | 2002-08-30 | 2007-07-09 | 에프. 호프만-라 로슈 아게 | Ｐｐａｒ알파 및 ｐｐａｒ감마 작용제로서의 신규한 2-아릴티아졸 화합물 |
| RU2296759C2 (ru) | 2002-09-12 | 2007-04-10 | Ф.Хоффманн-Ля Рош Аг | N-замещенные 1н-индол-5-пропионовые кислоты, фармацевтическая композиция, содержащая эти соединения, и их применение (варианты) |
| AR041481A1 (es) * | 2002-10-07 | 2005-05-18 | Hoffmann La Roche | Derivados de acido arilpropionico-oxazol y su uso como agonistas de ppar |
| CA2503117C (en) * | 2002-11-08 | 2010-12-21 | F. Hoffmann-La Roche Ag | Substituted 4-alkoxyoxazol derivatives as ppar agonists |
| RU2315767C2 (ru) | 2002-11-25 | 2008-01-27 | Ф.Хоффманн-Ля Рош Аг | Индолилпроизводные, способ их получения, фармацевтическая композиция, способ лечения и/или профилактики заболеваний |
| DE10308355A1 (de) | 2003-02-27 | 2004-12-23 | Aventis Pharma Deutschland Gmbh | Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel |
| US7244763B2 (en) | 2003-04-17 | 2007-07-17 | Warner Lambert Company Llc | Compounds that modulate PPAR activity and methods of preparation |
| EP1658285B1 (en) * | 2003-08-20 | 2007-05-02 | Eli Lilly And Company | Compounds, methods and formulations for the oral delivery of a glucagon like peptide (glp)-1 compound or an melanocortin 4 receptor (mc4) agonist peptide |
| ATE350369T1 (de) | 2003-08-20 | 2007-01-15 | Lilly Co Eli | Verbindungen, verfahren und formulierungen zur oralen verabreichung einer glucagon like peptide (glp)-1-verbindung oder eines am melanocortin-4- rezeptor (mc4) als agonist wirkenden peptids |
| WO2005100318A1 (en) * | 2004-04-14 | 2005-10-27 | Ranbaxy Laboratories Limited | Alkanoic acids and their esters as antidiabetic agents |
| JPWO2006057448A1 (ja) * | 2004-11-26 | 2008-06-05 | 武田薬品工業株式会社 | アリールアルカン酸誘導体 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5089514A (en) * | 1990-06-14 | 1992-02-18 | Pfizer Inc. | 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents |
| US5232945A (en) * | 1992-07-20 | 1993-08-03 | Pfizer Inc. | 3-aryl-2-hydroxypropionic acid derivatives and analogs as antihypertensives |
| US5902726A (en) * | 1994-12-23 | 1999-05-11 | Glaxo Wellcome Inc. | Activators of the nuclear orphan receptor peroxisome proliferator-activated receptor gamma |
| US6062509A (en) | 1994-12-23 | 2000-05-16 | Hexcel Corporation | Retrofit centerline luggage bin assemblies compatible with existing aircraft bin supports |
| AU721452B2 (en) | 1996-02-02 | 2000-07-06 | Merck & Co., Inc. | Antidiabetic agents |
| GB9604242D0 (en) * | 1996-02-28 | 1996-05-01 | Glaxo Wellcome Inc | Chemical compounds |
| CN1233241A (zh) * | 1996-08-19 | 1999-10-27 | 日本烟草产业株式会社 | 丙酸衍生物及其用途 |
| ATE451346T1 (de) | 1998-03-10 | 2009-12-15 | Ono Pharmaceutical Co | Carbonsäurederivate und medikamente die diese als aktiven wirkstoff enthalten |
| US6417212B1 (en) | 1999-08-27 | 2002-07-09 | Eli Lilly & Company | Modulators of peroxisome proliferator activated receptors |
| JP4316787B2 (ja) | 2000-01-11 | 2009-08-19 | 壽製薬株式会社 | エーテル又はアミド誘導体、その製法並びにそれを含有する糖尿病治療剤、 |
| JP2004509084A (ja) | 2000-08-23 | 2004-03-25 | イーライ・リリー・アンド・カンパニー | オキサゾリル−アリールオキシ酢酸誘導体およびそのｐｐａｒアゴニストとしての使用 |
| AU2001284660A1 (en) * | 2000-08-23 | 2002-03-04 | Eli Lilly And Company | Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists |
-
2001
- 2001-08-23 CA CA002418104A patent/CA2418104A1/en not_active Abandoned
- 2001-08-23 ES ES01963733T patent/ES2286137T3/es not_active Expired - Lifetime
- 2001-08-23 AU AU2001284659A patent/AU2001284659A1/en not_active Abandoned
- 2001-08-23 MX MXPA03001558A patent/MXPA03001558A/es unknown
- 2001-08-23 JP JP2002521432A patent/JP2004506721A/ja not_active Withdrawn
- 2001-08-23 BR BR0113409-4A patent/BR0113409A/pt not_active IP Right Cessation
- 2001-08-23 DK DK01963733T patent/DK1313716T3/da active
- 2001-08-23 WO PCT/US2001/022616 patent/WO2002016331A1/en not_active Ceased
- 2001-08-23 HU HU0300857A patent/HUP0300857A3/hu unknown
- 2001-08-23 CN CNA018177387A patent/CN1471517A/zh active Pending
- 2001-08-23 US US10/343,476 patent/US6930120B2/en not_active Expired - Fee Related
- 2001-08-23 DE DE60128239T patent/DE60128239T2/de not_active Expired - Lifetime
- 2001-08-23 AT AT01963733T patent/ATE361283T1/de not_active IP Right Cessation
- 2001-08-23 SK SK187-2003A patent/SK1872003A3/sk not_active Application Discontinuation
- 2001-08-23 KR KR10-2003-7002472A patent/KR20030027054A/ko not_active Withdrawn
- 2001-08-23 EP EP01963733A patent/EP1313716B1/en not_active Expired - Lifetime
- 2001-08-23 CZ CZ2003482A patent/CZ2003482A3/cs unknown
- 2001-08-23 IL IL15411001A patent/IL154110A0/xx unknown
- 2001-08-23 PT PT01963733T patent/PT1313716E/pt unknown
- 2001-08-23 NZ NZ523804A patent/NZ523804A/en unknown
- 2001-08-23 EA EA200300286A patent/EA200300286A1/ru unknown
- 2001-08-23 PL PL01360744A patent/PL360744A1/xx not_active Application Discontinuation
-
2003
- 2003-01-21 ZA ZA200300570A patent/ZA200300570B/en unknown
- 2003-02-14 NO NO20030729A patent/NO20030729L/no not_active Application Discontinuation
- 2003-03-06 EC EC2003004504A patent/ECSP034504A/es unknown
-
2005
- 2005-02-09 US US11/054,226 patent/US7345070B2/en not_active Expired - Fee Related
-
2007
- 2007-06-19 CY CY20071100810T patent/CY1107679T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20050245584A1 (en) | 2005-11-03 |
| EP1313716A1 (en) | 2003-05-28 |
| ES2286137T3 (es) | 2007-12-01 |
| EP1313716B1 (en) | 2007-05-02 |
| MXPA03001558A (es) | 2003-06-06 |
| NZ523804A (en) | 2004-09-24 |
| ZA200300570B (en) | 2004-04-21 |
| WO2002016331A1 (en) | 2002-02-28 |
| US6930120B2 (en) | 2005-08-16 |
| PL360744A1 (en) | 2004-09-20 |
| PT1313716E (pt) | 2007-07-11 |
| DK1313716T3 (da) | 2007-08-27 |
| JP2004506721A (ja) | 2004-03-04 |
| NO20030729D0 (no) | 2003-02-14 |
| HUP0300857A2 (hu) | 2003-10-28 |
| NO20030729L (no) | 2003-04-02 |
| IL154110A0 (en) | 2003-07-31 |
| US7345070B2 (en) | 2008-03-18 |
| CY1107679T1 (el) | 2013-04-18 |
| AU2001284659A1 (en) | 2002-03-04 |
| US20040097590A1 (en) | 2004-05-20 |
| DE60128239T2 (de) | 2008-01-10 |
| CA2418104A1 (en) | 2002-02-28 |
| ECSP034504A (es) | 2003-04-25 |
| CZ2003482A3 (cs) | 2003-05-14 |
| KR20030027054A (ko) | 2003-04-03 |
| EA200300286A1 (ru) | 2003-08-28 |
| HUP0300857A3 (en) | 2007-03-28 |
| SK1872003A3 (en) | 2003-07-01 |
| BR0113409A (pt) | 2003-07-01 |
| ATE361283T1 (de) | 2007-05-15 |
| DE60128239D1 (de) | 2007-06-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1164579C (zh) | 噻唑和噁唑衍生物以及它们的药物应用 | |
| CN1471517A (zh) | Cxazolyl-芳基丙酸衍生物及其作为过氧化物酶体增殖物活化受体激动剂的用途 | |
| CN1157368C (zh) | 人过氧化物酶体增殖剂活化受体(PPAR)α激动剂-取代苯基丙酸衍生物 | |
| CN1578659A (zh) | 过氧化物酶体增殖剂激活的受体(ppar)的调节剂 | |
| CN1252057C (zh) | 用于治疗与paar有关的疾病的噻唑衍生物 | |
| CN1235870C (zh) | 苯基杂烷基胺衍生物的新应用 | |
| CN1184215C (zh) | 作为HPPARα激活剂的、取代的噁唑与噻唑衍生物 | |
| CN1093124C (zh) | 对PPAR－γ具有激动剂活性的取代的4－羟基－苯基alcanoic acid衍生物 | |
| CN1215059C (zh) | 新的杂环化合物及其盐和它们的医药用途 | |
| CN1909902A (zh) | 用于治疗糖尿病的作为ppar调节剂的三唑、噁二唑和噻二唑衍生物 | |
| CN1543451A (zh) | 过氧化物酶体增生剂激活的受体的调节剂 | |
| CN1946666A (zh) | 用于治疗代谢性疾病的化合物、药物组合物和方法 | |
| CN101048402A (zh) | 咔唑衍生物、其溶剂合物或其药学上允许的盐 | |
| CN1095716A (zh) | 具有极好的降血糖活性的新颖化合物 | |
| CN1671659A (zh) | 新的取代吲哚 | |
| CN1942428A (zh) | Cetp抑制剂 | |
| CN1649820A (zh) | 调节ppar活性的化合物及其制备方法 | |
| CN101031540A (zh) | 六氟异丙醇取代的醚衍生物 | |
| CN1035178C (zh) | 芳酰胺衍生物 | |
| CN1886133A (zh) | 吲哚化合物 | |
| CN1111622A (zh) | 丙烯酸衍生物 | |
| CN1617854A (zh) | 苯基(烷基)羧酸衍生物和二酸苯基烷基杂环衍生物及其用作具有血清葡萄糖和/或血清脂降低活性的药物的应用 | |
| CN1753879A (zh) | 作为用于治疗2型糖尿病和动脉硬化症的ppar调节剂的3－(2－苯基－噁唑－4－基甲氧基)环己基甲氧基乙酸衍生物和相关化合物 | |
| CN1489582A (zh) | 二氢化萘衍生物及包含该衍生物作为活性成分的药物 | |
| CN1396904A (zh) | 新颖的化合物、它们的制备和用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |